It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Treatment Study for Radionecrosis after Radiosurgery for Brain Metastases

Clinical Trial Title: 
Randomized phase II study: Corticosteroids + bevacizumab vs. oorticosteroids + placebo (BeSt) for radionecrosis after radiosurgery for brain metastases.
Clinical Trial Protocol ID: 
17072502
Clinical Trial Investigator Name: 
Aidnag Z. Diaz, MD
Clinical Trial Protocol Description: 

This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of radionecrosis, which will be based on a clinical onset of symptoms and radiological findings of radionecrosis at 3-24 months following radiosurgery, with or without pathological confirmation.
  • Are 18 years of age and older.
  • Have no clinically significant cardiovascular disease.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Brain Tumors
Contact Phone: 
(312) 942-8892
Contact Name: 
Jean Gibson, RN, BSN